Search
Antithrombin Alfa
go.drugbank.com/drugs/DB11166ApprovedAntithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations.
Otamixaban
go.drugbank.com/drugs/DB06635InvestigationalIt is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.
Rocakinogene sifuplasmid
go.drugbank.com/drugs/DB16316InvestigationalRocakinogene sifuplasmid is under investigation in clinical trial NCT03491683 (INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-diagnosed Glioblastoma
ASP-8731
go.drugbank.com/drugs/DB17696InvestigationalDeveloped by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093]
Bacteroides thetaiotaomicron
go.drugbank.com/drugs/DB17879InvestigationalDeveloped by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.[A259892]
Sitamaquine
go.drugbank.com/drugs/DB04909InvestigationalSitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential
Debamestrocel
go.drugbank.com/drugs/DB17934InvestigationalDebamestrocel is under clinical development by BrainStorm Cell Therapeutics and is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).[L47266]
Tolcapone
go.drugbank.com/drugs/DB00323ApprovedInvestigationalWithdrawnTolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline ...
Gadoteric acid
go.drugbank.com/drugs/DB09132ApprovedInvestigational[A263141,A263106] Gadoterate is approved by the FDA under the brand name DOTAREM on 20th March 2013 for intravenous uses with magnetic resonance imaging (MRI) in the brain (intracranial), spine, and